Navigation Links
Endologix Appoints Dan Lemaitre to its Board of Directors
Date:12/10/2009

IRVINE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that Dan Lemaitre, former President and CEO of CoreValve, has joined the Endologix Board of Directors effective December 11, 2009. Endologix now has four independent directors and three non-independent directors.

Franklin D. Brown, Chairman of the Board, said, "We are pleased to welcome Dan Lemaitre to the Endologix Board of Directors. He has a proven track record in the medical device industry, with relevant experience in the endovascular sector and the investment community. We expect that Dan will provide valuable advice and strategic contributions as a Board member and I look forward to working with him as we continue to grow Endologix's business."

Mr. Lemaitre most recently served as the President and CEO of CoreValve, a private company focused on percutaneous aortic valve replacement. CoreValve was acquired by Medtronic in April 2009 for $700 million and $150 million of potential milestone payments. Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years in the medical device field as an investment analyst. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch.

Mr. Lemaitre holds a BA in Economics from Bethany College and an MBA from Bowling Green State University. He is a Chartered Financial Analyst.

The appointment of Mr. Lemaitre also brings the Company back into compliance with Nasdaq's Marketplace Rule 4350(c), which requires the Company to maintain a Board that is comprised of a m
'/>"/>

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. ... develops and commercializes proprietary technologies and products for advanced ... been approved for trading in the United ... is expected to commence on September 17, 2014 on ... continue to trade on the TSX Venture Exchange under ...
(Date:9/17/2014)... de septiembre de 2014  Cryoport, Inc. ... mundial de soluciones logísticas avanzadas criogénicas para ... vida, anunció hoy la contratación de Broekman ... sede en Rótterdam, Países Bajos, para proporcionar ... en rápido crecimiento. Según los términos del ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
Breaking Biology Technology:Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... Global Products, BASINGSTOKE, England, October 8 ... global specialty biopharmaceutical,company, announces that it has agreed ... Almirall for a cash consideration of $213m. The ... sodium),and VANIQA(R) (eflornithine hydrochloride), and six other non-promoted,products1 ...
... about the origins of quantum dot blinking, researchers ... Laboratory, the University of Chicago and the California ... characterize it on faster time scales than have ... also known as quantum dots, are being intensively ...
... to Vice President, Research Operations ... Non-Profit Foundation, CARLSBAD, Calif., Oct. 5 ... focused on the discovery and,development of small-molecule therapeutics ... diseases, today announced changes to its,research management. Dr. ...
Cached Biology Technology:Shire Divests Non-Core Product Portfolio to Almirall 2Shire Divests Non-Core Product Portfolio to Almirall 3Argonne researcher studies what makes quantum dots blink 2Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
(Date:9/15/2014)... from digestion to disease resistance. Despite the fact that ... the planet, more is known about belly-button bacteria than ... colleagues working on Panama,s Barro Colorado Island discovered that ... to more than 400 different kinds of bacteria. The ... 7,000 different kinds. , Bacteria in tropical forests may ...
(Date:9/15/2014)... that lowland tapir populations may continue to drop in ... from the Office National de la Chasse et de ... Zoo Global reviewed data retrieved from camera traps in ... and compared this data to current harvest rates in ... tapirs in French Guiana," said Matthias Tobler, a scientist ...
(Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... University of Delaware have developed a "smart" hydrogel that can ... Over the past few decades, smart hydrogels have been created ... "The idea of a smart hydrogel that can release ... professor of materials science and engineering and biomedical engineering. "What,s ...
... Living organisms have adapted to the day-night cycle and, in ... are not completely known yet but its functioning has been ... of normal circadian rhythms can have deleterious effects on health; ... the time of feeding was shown to affect the ability ...
... of the white-throated sparrow has identified a biological pathway connecting ... wild to variation in their genome. The Proceedings ... is publishing the results of the experiments, conducted by the ... Psychology. The research, which comprised behavioral observations ...
Cached Biology News:UD-developed smart gels deliver medicine on demand 2The internal clock and feeding rhythm set the pace of the liver 2Wild sparrow study traces social behaviors in the field to specific gene 2Wild sparrow study traces social behaviors in the field to specific gene 3Wild sparrow study traces social behaviors in the field to specific gene 4
... Anti-Natural Killer Cell Receptor-P1, ... Immunogen: Hybridoma produced ... from BALB/c mice immunized (BALB/c ... (LAK) cells and mouse myeloma ...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: